Elevated serum mesothelin values were observed in 12% of women with early-stage lesions (FIGO I, II) and in 48% of women with advanced stages of ovarian cancer (FIGO III and IV), with a test specificity of 95%. Here, MSLN is linked to ovarian cancer.